Celebrating 25 years Est 1999-2024
*Across 3 years $3395.52 only $1358.21
First subject dosed in phase I clinical study with eye-drop formulation of laquinimod Lund, December 10, 2021 - Active Biotech (NASDAQ...
Data on naptumomab estafenatox enhancing CAR-T cells potency presented by Active Biotech’s partner NeoTX at SITC 2021 Lund, Sweden — November...
Active Biotech’s partner NeoTX to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Lund, November 9, 2021 - Active...
New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH) Lund, November 4, 2021...
Active Biotech Interim report January - September 2021 “We have seen the first encouraging results from the ongoing tasquinimod...
Active Biotech and NeoTX today announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox in...
Active Biotech: Tasquinimod clinical development in multiple myeloma advances into combination therapy following completion of the initial...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.